Oral SERD Promising in ER-Positive Breast Cancer With ESR1 Mutations

The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective response rate among 40 heavily pretreated women with estrogen receptor (ER)-positive, HER2-negative breast cancer. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rxLdS9
via IFTTT